Hereditary Angioedema Hae clinical trials

Explore recruiting hereditary angioedema hae clinical trials.

Recruiting hereditary angioedema hae studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hereditary Angioedema Hae trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal on the Bioavailability of a 40 mg Extended-Release (XR) Deucrictibant Oral Formulation Administered as a Single Dose.

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants with Hereditary Angioedema (The ALPHA-STAR Trial)

Czechia, Poland, Bulgaria, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]

Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

France, Hungary, Italy, Slovakia, Germany, Ireland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)

Germany, France, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients with Hereditary Angioedema (The ALPHA-SOLAR Trial)

Poland, Germany, Bulgaria, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Hereditary Angioedema Hae trials by city

Hereditary Angioedema Hae in Toronto Hereditary Angioedema Hae in Vancouver Hereditary Angioedema Hae in Montreal Hereditary Angioedema Hae in Calgary Hereditary Angioedema Hae in Edmonton Hereditary Angioedema Hae in Ottawa Hereditary Angioedema Hae in Winnipeg Hereditary Angioedema Hae in Quebec City Hereditary Angioedema Hae in Hamilton Hereditary Angioedema Hae in Kitchener Hereditary Angioedema Hae in London Hereditary Angioedema Hae in Halifax Hereditary Angioedema Hae in New York Hereditary Angioedema Hae in Los Angeles Hereditary Angioedema Hae in Chicago Hereditary Angioedema Hae in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease